Mixtard 50 Penfill (Insulin Human)

Insulin human mimics the action of natural human insulin. After subcutaneous injection, it binds to insulin receptors on muscle, fat and liver cells, triggering pathways that increase glucose uptake, promote glycogen storage, and suppress hepatic glucose production, thereby lowering circulating glucose concentrations.

The dose of Mixtard 50 Penfill is individualized. A qualified prescriber calculates the required units based on the patient’s current blood‑glucose readings, body weight, diet, activity level, and any concurrent medications. The prescriber then provides a specific dosing regimen that the patient follows.

Insulin is generally considered the preferred glucose‑lowering therapy during pregnancy because it does not cross the placenta in significant amounts. However, Mixtard 50 Penfill should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Mixtard 50 Penfill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and any necessary import documentation.

Mixtard 50 Penfill contains human insulin, which has a rapid onset and short duration compared with some long‑acting analogues. It is suitable for basal‑bolus regimens and offers flexibility in dose titration. Compared with insulin analogues, it may be less expensive but requires careful timing around meals to avoid hypoglycemia.

Mixtard 50 Penfill must be stored in a refrigerator at 2‑8 °C. Keep the pen in its original carton, protect it from light, and do not freeze or shake the device. Once in use, most pens can be kept at controlled room temperature (up to 30 °C) for a limited number of days, as indicated on the label.

Mixtard 50 Penfill is administered by subcutaneous injection. The user selects the prescribed dose on the pen’s dial, attaches a new needle, and injects into a fatty tissue area such as the abdomen, thigh or upper arm. Proper technique, rotation of injection sites and disposal of used needles are essential for safety.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia, monitor glucose frequently, and seek immediate medical attention if a severe reaction occurs.

Mixtard 50 Penfill should be avoided in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia at the time of administration. Clinicians should assess each patient’s medical history before initiating therapy.